Abdomen Tumors, Gynecologic Cancer, Malignant Melanoma, Thoracic Cancer
Conditions
Brief summary
Consecutive patients treated with PD-1 therapy in Qingdao City were included in our study. The effecy and safety of the four PD-1 agents according to clinical outcomes in real world will be studied.
Detailed description
Consecutive patients treated with PD-1 therapy in Qingdao City were included in our study. The effecy and safety of the four PD-1 agents according to clinical outcomes in real world will be studied. ORR will be studied of the four PD-1 agents（nivolumab, pembrolizumab, toripalimab, sintilimab）
Interventions
DRUGChemotherapy
compare the effecy and safety of 4 PD-1 agents single and combined with chemotherapy in chinese people.
Sponsors
The Affiliated Hospital of Qingdao University
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Patients with lung cancer, liver cancer and other solid cancers * Histologically or cytologically confirmed diagnosis cancer treated with PD-1 agents * At least one measurable lesion * Eastern Cooperative Oncology Group (ECOG) Performance Scale 0 or 1 Adequate organ function
Exclusion criteria
* patients treated with PD-1 agents less than 2 terms
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Response Rate (ORR) | 1 year | ORR was defined as the percentage of participants in the analysis population who had a Complete Response (CR; disappearance of all target lesions) or Partial Response (PR; at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters). The percentage of strongly PD-L1 positive participants who experienced a CR or PR is presented. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Experiencing Adverse Events (AEs) | 1 year | Adverse events are defined as any adverse medical events that occur in the participants taking the drugs and do not necessarily have a causal relationship with the treatment. |
Other
| Measure | Time frame | Description |
|---|---|---|
| PFS | 2 years | PFS was defined as the time from the first day of study treatment to the first documented disease progression per irRC or death due to any cause, whichever occurred first. |
Countries
China
Contacts
Primary ContactXiaochun Zhang, Dr
Backup ContactMan Jiang, Dr
Outcome results
None listed